Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia?

Haemophilia. 2016 Jul;22(4):e347-8. doi: 10.1111/hae.12977. Epub 2016 Jun 28.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anemia / etiology
  • Angiodysplasia / complications
  • Angiodysplasia / diagnosis
  • Angiodysplasia / drug therapy*
  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Electrocoagulation
  • Endoscopy, Digestive System
  • Female
  • Hemoglobins / analysis
  • Hemorrhage / prevention & control
  • Humans
  • Melena / etiology
  • Middle Aged
  • Platelet Transfusion
  • Somatostatin / therapeutic use
  • Thrombasthenia / complications
  • Thrombasthenia / diagnosis*

Substances

  • Angiogenesis Inhibitors
  • Hemoglobins
  • Bevacizumab
  • Somatostatin